Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inobrodib - CellCentric

Next Previous
Drug Profile

Inobrodib - CellCentric

Alternative Names: CCS-1477

Latest Information Update: 06 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CellCentric
  • Class Antineoplastics; Fluorobenzenes; Imidazoles; Isoxazoles; Piperidines; Small molecules
  • Mechanism of Action P300-CBP transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours
  • Preclinical Malignant melanoma
  • No development reported Bladder cancer; Lung cancer

Most Recent Events

  • 31 Jul 2025 CellCentric plans a phase II trial for Multiple myeloma (Second-line therapy or greater, Combination therapy) in United Kingdom (PO) in December 2025 (NCT07096778)
  • 06 Jul 2025 CellCentric completes phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy) in USA, Sweden, Spain, Netherlands, France, United Kingdom (PO) (NCT03568656)
  • 19 May 2025 CellCentric plans accelerated approval pathway for Multiple myeloma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top